Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary thrombosis

Expert Opinion on Investigational Drugs

Volumn 6, Issue 11, 1997, Pages 1623-1642

  Winkelmann, B R ^a   Zahn, R ^a   Stilz, H U ^a  

^a Heart Center Ludwigshafen   (Germany)

Author keywords

Abciximab; Eptifibatide; Glycoprotein; Glycoprotein IIb IIIa; IIb IIIa receptor blockade; Intravenous; Lamifiban; Oral; Tirofiban

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; INTEGRIN; LAMIFIBAN; RECEPTOR BLOCKING AGENT; THROMBOCYTE RECEPTOR; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; HUMAN; RECEPTOR BLOCKING; REVIEW; THROMBOCYTE ACTIVATION;

EID: 0030690333     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.11.1623     Document Type: Review

References (68)